Medicinal chemistry; drug design and development in the areas of anti-vessication agents, vasopressin antagonists, dermatologicals, and cholinesterase inhibitors.
As you might expect, I teach courses in the area of my research expertise. These include a graduate course in synthesis, one in heterocyclic compounds, another in medicinal and pharmaceutical chemistry, and a "gateway" course on organic reaction mechanisms.
Recent Publications and Patents:
Since 2009: Selected from >260 Since l961
Fabio KM, Guillon CD, Lu S-F, Heindel ND, Brownstein MJ, Lacey CJ, Garippa C, Simon NG. Pharmacokinetics and metabolism of SRX246:A potent and selective vasopressin 1a antagonist. J Pharm Sci. 2013, 102: 2033-2043.
Laskin JD, Heck DE, Lacey CJ, Aponte E, Huang M-T, Heindel ND, Pharmacologically-active vanilloid carbamates, U.S.Patent 8,343,971, issued 31 December 2012
Haddad GL, Young SC, Heindel ND, Bornhop DJ, Flowers RA 2nd, Back-scattering interferometry:an ultrasensitive method for the unperturbed detection of acetylcholinesterase-inhibitor interactions, Angew Chem Int Ed Engl. 2012 Oct 29;51(44):11126-30
Heindel ND and Rapp RD, The Nineteenth-Century Horse Doctor: A Pennsylvania Dutchman’s Practical Guide to Treating Horses, Coffeetown Press, Seattle, WA, 2012, ISBN 978-1-60381-121-7
Fabio K, Guillon C, Lacey CJ, Lu S-F, Heindel ND, Ferris C F, Placzek M, Jones G, Brownstein MJ, Simon NG. Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging. Bioorg & Med Chem, 2012, 20: 1337-1345. Doi:10.1016/j.bmc/2011.12.013.
Laskin JD, Fabio K, Lacey CJ, Young S, Mohanta P, Guillon CD, Heindel ND, Huang M-T, Heck DE, Unique Dual-Action Therapeutics, U. S. Patent Pending, PCT/US2009/005961, Pub. No. US2012/0010168 A1, published January 12, 2012.
Young, SC, Fabio KM, Huang M-T, Saxena J, Harman M P, Guillon CD, Vetrano AM, Heck DE. Flowers RA II, Heindel ND and Laskin JD (2012), Investigation of anticholinergic and non-steroidal anti-inflammatory prodrugs which reduce chemically induced skin inflammation. Journal of Applied Toxicology, 2012, 32: 135-141. doi: 10.1002/jat.1645
Laskin JD, Heck DE, Heindel ND, Dimethyl amino ethyl ether psoralens and methods for their production and use. Issued 6 December 2011, U.S. Patent 8,071,642 (2011)
Young SC, Fabio KM, Guillon C, Mohanta P, Halton TA, Heck DE, Flowers RA, Laskin JD, Heindel ND, Peripheral site acetylcholinesterase inhibitors targeting both inflammation and cholinergic dysfunction, Biorg and Med Chem Lett. 2010, 20:2987-2990. PMID: 20347302 doi:10.1016/j.bmcl.2010.02.102
Shakarjian MP, Heck DE, Gray JP, Sinko PJ, Gordon MK, Casillas RP, Heindel ND, Gerecke DR, Laskin DL, Laskin JD. Mechanisms mediating the vesicant actions of sulfur mustard after cutaneous exposure. Toxicol Sci. 2010, 114(1):5-19. PMID: 19833738
Gordon MK, DeSantis A, Deshmukh M, Lacey CJ, Hahn RA, Beloni J, Anumolu SS, Schlager JJ, Gallo MA, Gerecke DR, Heindel ND, Svoboda KKH, Babin MC and Sinko PJ, Doxycycline Hydrogels as a Potential Therapy for Ocular Vesicant Injury, Journal of Ocular Pharmacology and Therapeutics, 2010, 5: 407-419.
Fabio K, Guillon CD, Lu S-F, Heindel ND, Miller MJ, Ferris CF, Brownstein MJ, Garripa C, Steiner M, Coccaro E, Damiano E, Koppel GA, Simon NG, Vasopressin Antagonists as Anxiolytics and Antidepressants: Recent Developments. Frontiers in CNS Drug Discovery, 2010, 1, 156-183.
Laskin JD, Heck DE, Huang M-T, Fabio K, Lacey CJ, Young S, Mohanta P, Guillon CD, Heindel ND, Preparation of phenyl carbonate derivatives as reversible inhibitors of acetylcholinesterase, PTC Int, Appl. (2010) WO Patent No. 2010051044 A1 20100506. Accession Number 2010:563796; CAN 152:501184
Jeffrey D. Laskin, Diane E. Heck, C. Jeffrey Lacey, Erik Aponte, Mou-Tuan Huang, and Ned D. Heindel, Vanilloid Carbamates of Pharmacological Utility as Inhibitors of Fatty Acid Amide Hydrolase, Modulators of TRPV1, and Suppressors of Inflammation, Patent Pending, #RWJ 09-52, September 14, 2009.
Laskin JD, Heindel N, Heck D, Vetrano AM, Guillon C, DeMatteo P, Fluorescent Fused-Ring Triazoles that Inhibit Cell Proliferation and Uses Thereof, U.S.Patent 7,598,238 (2009)
M. P. Shakarjian, D. E. Heck, J. Gray, P. J. Sinko, M. K. Gordon, R.P. Casillas, N. D. Heindel, D. R. Gerecke, D.L. Laskin, and J. D. Laskin, Mechanisms mediating the vesicant actions of sulfur mustard after cutaneous exposure, Tox. Sci. Advanced Access, 108: 15 October 2009, pp 1-43.
C. Guillon, G. Koppel, N. Heindel /et al/. “Azetidinones as vasopressin V1a antagonists,” Bioorg. & Med. Chem., *15* (2007) 2054-2080.
C. F. Ferris, S-f Lu, T. Messenger, C. D. Guillon, N. Heindel, M. Miller, G. Koeppel, F. R. Bruns, and N. G. Simon, “Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior,” Pharmacology, Biochemistry and Behavior, *83* 2006 169-174.
J. D. Laskin, C. Martey, N. D. Heindel, M. Whittemore, and D. Heck, * “*Fluorescent Tags for Amino Acid and Nucleic Acid Analysis*,”* U.S. Patent 7,150,967 (2006)
J. D. Laskin, D. Heck, N. D. Heindel, A. M. Vetrano, C. Guillon, P. DeMatteo, “Fluorescent Fused-Ring Triazoles that Inhibit Cell Proliferation,” U.S. Patent 7,105,511 (2006)
R. F. Bruns, C. Guillon, N. D. Heindel, G. A. Koppel, M. Miller, Beta-Lactamyl Vasopressin Antagonists,” U.S.Patent 7,119,083 (2006).
N. D. Heindel, Tina Masciangioli, and Eva von Schaper, eds., “Are Chemistry Journals too Expensive and Inaccessible?,” National Academies Press, ISBN 0-309-09590-5, Washington, DC, 2005.